Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 22:9:3465-79.
doi: 10.2147/IJN.S60488. eCollection 2014.

Nanopharmacology in translational hematology and oncology

Ciprian Tomuleasa  1 , Cornelia Braicu  2 , Alexandra Irimie  3 , Lucian Craciun  2 , Ioana Berindan-Neagoe  4
Affiliations
Review

Nanopharmacology in translational hematology and oncology

Ciprian Tomuleasa et al. Int J Nanomedicine. .

Abstract

Nanoparticles have displayed considerable promise for safely delivering therapeutic agents with miscellaneous therapeutic properties. Current progress in nanotechnology has put forward, in the last few years, several therapeutic strategies that could be integrated into clinical use by using constructs for molecular diagnosis, disease detection, cytostatic drug delivery, and nanoscale immunotherapy. In the hope of bringing the concept of nanopharmacology toward a viable and feasible clinical reality in a cancer center, the present report attempts to present the grounds for the use of cell-free nanoscale structures for molecular therapy in experimental hematology and oncology.

Keywords: hematological malignancies; nanoparticles; translational medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nanoparticles used in medicine.
Figure 2
Figure 2
miRNA-based approaches in cancer therapy. Abbreviation: miRNA, micro ribonucleic acid.
Figure 3
Figure 3
Bench-to-bedside evolution in translational hematology and oncology. Abbreviations: FFPE, formalin-fixed, paraffin-embedded; miRNA, micro ribonucleic acid; qRT-PCR, quantitative real-time polymerase chain reaction.
See this image and copyright information in PMC

References

    1. de Morais MG, Martins VG, Steffens D, Pranke P, da Costa JA. Biological applications of nanobiotechnology. J Nanosci Nanotechnol. 2014;14(1):1007–1017. - PubMed
    1. Liang XJ. Nanotechnology and cancer nanomedicine. Biotechnol Adv. 2014;32(4):665. - PubMed
    1. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11:159. - PMC - PubMed
    1. Singh S, Sharma A, Robertson GP. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res. 2012;72(22):5663–5668. - PMC - PubMed
    1. Orza A, Soriţău O, Tomuleasa C, et al. Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine. 2013;8:689–702. - PMC - PubMed

Publication types

LinkOut - more resources